CombiGene signs agreement with Panion Animal Health for the licensing of the drug candidate for the veterinary market
CombiGene AB har genom att kombinera framsteg inom neurovetenskap och modern genteknik utvecklat en behandlingsmetod som i prekliniska studier visat sig kunna förhindra epilepsianfall. CombiGenes avsikt är att vidareutveckla denna behandlingsmetod för sjukvården så att den kan komma epilepsipatienter till godo.
Läs mer >>
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 email@example.com.